Clinical predictors for the prognosis of myasthenia gravis

BMC Neurology

Table 1 Relapse of myasthenia gravis

	RMG	NRMG	NA	P-value	Time of recurrence(month)			P-value
	RMG	NRMG	NA	P-value	≤6	7–12	>12	P-value
Sample size	26	51	6		11	6	9
Age of onset(year)^b	26	51		0.176	11	6	9	0.464
Age of onset(year)^c
≤ 40	10	25		0.262	4	4	2	0.219
> 40	16	26			7	2	7
Sex
Male	11	27		0.261	4	3	4	0.851
Female	15	24			7	3	5
Thymus
Normal	2	8		0.739	1	1	0	0.339
Thymic hyperplasia	12	24			6	1	5
Thymoma	9	15			3	2	4
NA	3	4			1	2	0
Other autoimmune disease
No	15	43			6	4	5
Yes	11	8		0.012	5	2	4	0.878
Symptom of onset
OMG	21	34	4	0.152	11	4	6	0.103
GMG	5	17	2		0	2	3
IIa	2	0		0.307^a	0	0	0	1.000^a
IIb	10	2			0	1	1
III	1	2			0	1	1
IV	4	1			0	0	1
Symptom of OMG onset
Sample size	21	34			11	4	6
Ptosis	14	21		0.443	7	4	3	0.310
Diplopia	3	3			2	0	1
Both	4	10			2	0	2
Ptosis
Sample size	14	21			7	4	3
Left	3	2		0.133	2	1	0	0.323
Right	4	14			1	1	2
Bilateral	7	5			4	2	1

NA: not available, Both: concurrence of ptosis and diplopia, RMG: relapse of MG, NRMG: no relapse of MG, GMG: patients presenting with generalized symptoms at disease onset, OMG: patients presenting with pure ocular MG at disease onset, Time of recurrence (month): based on the duration between the time of relapse and the time of first symptom onset of MG
^aDifference of MGFA grades between RMG and NRMG
^bAge at onset was not divided into two groups (statistical analysis using correlation matrix)
^cAge at onset was divided into two groups (statistical analysis using chi-square or fisher exact test)

ISSN: 1471-2377